ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with active brain metastases. The updated Phase 1/2 trial now contains more mature data … Continue reading Today’s Watch List : Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Oracle Corporation (NYSE:ORCL), JGWPT Holdings Inc. (NYSE:JGW), Argan, Inc. (NYSE:AGX), The Allstate Corporation (NYSE:ALL)